Lupus nephritis Medical Services in China

Lupus nephritis (LN) is a severe, immune-mediated kidney complication of systemic lupus erythematosus (SLE), characterized by inflammation and damage to the glomeruli, tubules, interstitium, and vasculature of the kidneys. It occurs when autoantibodies—particularly anti-double-stranded DNA (anti-dsDNA) and anti-nuclear antibodies—form immune complexes that deposit in renal tissues, triggering complement activation, leukocyte infiltration, and cytokine-driven inflammation. This cascade leads to progressive glomerular injury, proteinuria, hematuria, hypertension, and, if untreated, irreversible fibrosis and end-stage kidney disease. LN affects approximately 30–60% of SLE patients over their lifetime, with higher incidence among individuals diagnosed with SLE before age 40. Epidemiologically, LN disproportionately impacts women (female-to-male ratio ~9:1), particularly those of African, Hispanic, Asian, and Indigenous descent—populations exhibiting both higher SLE prevalence and more aggressive renal involvement. Key risk factors include genetic susceptibility (e.g., variants in IRF5, STAT4, HLA-DR2/DR3), early-onset SLE (<20 years), persistent high disease activity, serologic markers like low C3/C4 and elevated anti-dsDNA titers, and socioeconomic barriers to timely care. Beyond physical morbidity, LN significantly impairs quality of life: chronic fatigue, pain, cognitive dysfunction ('lupus fog'), anxiety and depression are common; treatment-related side effects—including corticosteroid-induced weight gain, osteoporosis, diabetes, and infection risk—further diminish functional capacity and psychosocial well-being. Patients often face work disability, reduced social participation, and caregiver dependency, especially during flares or dialysis-dependent stages. Early diagnosis via urine analysis (proteinuria >0.5 g/day, active sediment), serum creatinine, eGFR, and confirmatory renal biopsy (classified per ISN/RPS 2003 criteria) is critical. Without intervention, up to 10–30% of LN patients progress to end-stage kidney disease within 10 years. Modern management emphasizes immunosuppression tailored to histopathologic class (e.g., Class III/IV treated with mycophenolate mofetil or cyclophosphamide plus glucocorticoids; Class V with calcineurin inhibitors), alongside rigorous blood pressure control (target <120/80 mmHg), RAAS blockade, and lifestyle optimization. Emerging biologics—including belimumab (approved for active LN) and voclosporin (FDA-approved for active LN)—are reshaping therapeutic paradigms toward improved renal preservation and reduced steroid burden.

Lupus nephritis (LN) is a severe renal manifestation of systemic lupus erythematosus (SLE), characterized by immune-mediated inflammation and damage to the glomeruli, tubules, interstitium, and vasculature of the kidneys. It affects approximately 30–60% of SLE patients over the disease course and remains a leading cause of morbidity and mortality in this population. LN is not caused by a single etiologic agent but arises from a complex interplay of genetic susceptibility, dysregulated adaptive and innate immunity, loss of self-tolerance, and environmental exposures that collectively drive pathogenic autoantibody production—particularly anti-double-stranded DNA (anti-dsDNA) antibodies—and immune complex deposition in the renal parenchyma.

The primary immunopathogenic mechanism involves the formation of circulating immune complexes containing nuclear autoantigens (e.g., dsDNA, histones, nucleosomes) and autoantibodies. These complexes deposit in glomerular basement membranes, mesangial areas, or subendothelial/subepithelial spaces, triggering complement activation (notably C1q, C3, and C4), recruitment of inflammatory cells (neutrophils, macrophages, T lymphocytes), and release of cytokines (e.g., IFN-α, IL-6, BAFF), chemokines, and reactive oxygen species. This cascade results in endothelial injury, podocyte effacement, crescent formation, fibrosis, and progressive loss of renal function. Intrinsic renal cells—including podocytes and tubular epithelial cells—also contribute actively to inflammation via aberrant expression of toll-like receptors (TLR7/9), interferon-stimulated genes, and antigen presentation molecules.

Genetic factors confer substantial risk: genome-wide association studies (GWAS) have identified over 100 susceptibility loci associated with SLE and LN. High-risk alleles include HLA-DR2 (DRB1*15:01) and HLA-DR3 (DRB1*03:01), which influence antigen presentation and autoreactive T-cell activation. Non-HLA variants in IRF5, STAT4, ITGAM, TNFAIP3, and BANK1 modulate type I interferon signaling, B-cell activation, neutrophil adhesion, and NF-κB regulation. Notably, APOL1 G1/G2 risk variants—predominantly in individuals of recent African ancestry—are strongly associated with more aggressive LN phenotypes, earlier onset of end-stage kidney disease (ESKD), and poorer response to immunosuppression, independent of socioeconomic confounders.

Environmental triggers act on genetically predisposed individuals to initiate or exacerbate LN. Ultraviolet (UV) radiation induces keratinocyte apoptosis, increases surface expression of nuclear antigens, and promotes dendritic cell activation and IFN-α production—potentially precipitating renal flares. Epstein-Barr virus (EBV) infection is epidemiologically linked to SLE onset; molecular mimicry between EBV nuclear antigen-1 (EBNA-1) and Ro/Sm autoantigens may break tolerance. Other infectious agents—including cytomegalovirus and parvovirus B19—may similarly trigger cross-reactive immunity. Silica dust exposure, cigarette smoking, and certain medications (e.g., hydralazine, procainamide, isoniazid) are established environmental risk factors for SLE development and may contribute to renal involvement through epigenetic modifications (e.g., global DNA hypomethylation) and enhanced autoantigen exposure.

Demographic and clinical risk factors further stratify LN susceptibility and prognosis. Female sex (female-to-male ratio ~9:1 in reproductive years) reflects hormonal influences—estrogen enhances B-cell survival and antibody production, while prolactin augments autoreactive lymphocyte activity. Age at SLE onset <30 years correlates with higher LN incidence and severity. Ethnicity is a major determinant: Black, Hispanic, and Asian populations exhibit 2–4-fold higher prevalence and more aggressive histopathological classes (e.g., Class IV, IV+V) compared with White individuals—partly attributable to genetic, socioeconomic, and healthcare access disparities. Hypertension, obesity, and chronic viral infections (e.g., HIV, hepatitis C) worsen renal outcomes. Poor medication adherence, delayed diagnosis, and suboptimal control of extrarenal disease activity also increase flare risk and accelerate fibrosis. Importantly, while LN is not directly inherited, first-degree relatives of LN patients carry elevated polygenic risk for SLE and related autoimmune conditions, underscoring the importance of familial screening and early rheumatologic evaluation in high-risk cohorts.

Lupus nephritis (LN) is a severe, immune-mediated glomerulonephritis that occurs as a major renal manifestation of systemic lupus erythematosus (SLE). It affects approximately 30–60% of adult SLE patients and up to 80% of pediatric SLE cases, representing the leading cause of morbidity and mortality in this population. Early recognition and accurate characterization are critical to preserving renal function and preventing irreversible damage.

Early symptoms of lupus nephritis are often subtle and nonspecific, frequently overlooked or attributed to other conditions. Patients may report persistent fatigue, low-grade fever, mild arthralgias, or unexplained weight gain—symptoms commonly associated with active systemic lupus but not yet clearly linked to renal involvement. Subtle urinary changes—including asymptomatic microscopic hematuria, isolated proteinuria (<0.5 g/day), or mild elevation in serum creatinine—may be the only initial laboratory abnormalities. Some patients develop nocturia or frothy urine due to subnephrotic proteinuria before overt edema appears. Importantly, up to 20% of patients present with *silent* renal disease: normal urinalysis and serum creatinine at baseline, yet histopathologic evidence of active glomerular inflammation on biopsy. Thus, routine screening—including urinalysis, quantification of urine protein-to-creatinine ratio (UPCR), and serum creatinine with estimated glomerular filtration rate (eGFR)—is mandatory in all newly diagnosed or flaring SLE patients, regardless of symptomatology.

Typical symptoms reflect progressive glomerular injury and include peripheral edema (especially periorbital and lower extremity), hypertension (often new-onset or worsening), and signs of nephrotic syndrome: heavy proteinuria (>3.5 g/24 h), hypoalbuminemia (<3.0 g/dL), hyperlipidemia, and clinical edema. Macroscopic hematuria may occur but is less common than microscopic hematuria. Active urinary sediment typically reveals dysmorphic red blood cells, red blood cell casts, and granular or hyaline casts—hallmarks of glomerular pathology. Patients may also exhibit oliguria or rapidly declining eGFR, particularly in proliferative forms (Class III or IV LN). In severe cases, acute kidney injury (AKI) can develop over days to weeks, necessitating urgent evaluation.

Accompanying systemic symptoms frequently coexist and support the diagnosis of SLE-related renal disease. These include malar or discoid rash, photosensitivity, oral ulcers, alopecia, pleuritis or pericarditis, non-erosive arthritis, neuropsychiatric manifestations (e.g., seizures, psychosis), cytopenias (leukopenia, lymphopenia, thrombocytopenia), and positive serologies—most notably anti-nuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA) antibodies, and hypocomplementemia (low C3, C4, CH50). Elevated anti-dsDNA titers and falling complement levels often precede or parallel renal flares. Urinary biomarkers such as monocyte chemoattractant protein-1 (MCP-1), neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1) are under investigation but not yet standard for clinical diagnosis.

Complications of untreated or refractory lupus nephritis are substantial. Chronic kidney disease (CKD) develops in ~25% of patients within 10 years; end-stage kidney disease (ESKD) requiring dialysis or transplantation occurs in 10–20% over 15–20 years. Thrombotic microangiopathy (TMA), especially in association with antiphospholipid syndrome, may precipitate cortical necrosis or malignant hypertension. Cardiovascular complications—including accelerated atherosclerosis, myocardial infarction, and stroke—are markedly increased due to chronic inflammation, corticosteroid use, and traditional risk factors. Infections (e.g., pneumonia, urinary tract infection, opportunistic pathogens like Pneumocystis jirovecii) represent the leading cause of death in LN, largely attributable to immunosuppressive therapy. Pregnancy complications—including preeclampsia, preterm birth, fetal growth restriction, and maternal renal flare—are significantly elevated, particularly if LN is active or recently quiescent (<6 months remission). Additionally, patients face heightened risks of malignancy (e.g., lymphoma, cervical cancer) and osteoporosis-related fractures.

Diagnosis of lupus nephritis requires integration of clinical, laboratory, and histopathologic data. Renal biopsy remains the gold standard—not only for confirming LN but also for classifying histopathologic patterns according to the International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2018 classification: Class I (minimal mesangial), II (mesangial proliferative), III (focal), IV (diffuse), V (membranous), and VI (advanced sclerosing). Biopsy guides prognosis and therapeutic decisions: Class IV-LN carries the highest risk of progression to ESKD, while Class V often presents with nephrotic-range proteinuria but slower decline in GFR. Ancillary tests include quantitative 24-hour urine protein, UPCR, serum creatinine, cystatin C–based eGFR, complete blood count, comprehensive metabolic panel, complement levels (C3, C4), anti-dsDNA, ANA, anti-Smith (anti-Sm), anti-RNP, and antiphospholipid antibodies. Urine microscopy must be performed fresh to identify cellular casts. Imaging (renal ultrasound) assesses kidney size and echogenicity but lacks specificity; Doppler may detect renal artery stenosis or venous thrombosis in complex cases.

Differential diagnosis is essential to avoid misattribution and inappropriate immunosuppression. Primary glomerular diseases—including IgA nephropathy (often with preceding mucosal infection and preserved C3), membranous nephropathy (typically anti-PLA2R–positive, without systemic features), and pauci-immune vasculitides (e.g., ANCA-associated vasculitis presenting with crescentic GN and pulmonary-renal syndrome)—must be excluded. Other secondary causes include hepatitis B/C–associated membranoproliferative GN, HIV-associated nephropathy (collapsing variant), and drug-induced lupus (e.g., hydralazine, procainamide) which rarely causes true nephritis. Post-infectious GN usually follows streptococcal infection and shows transient hypocomplementemia with spontaneous resolution. Amyloidosis and diabetic nephropathy may mimic LN clinically but lack characteristic serologic markers and show distinct histopathology (e.g., Congo red positivity, nodular glomerulosclerosis). Finally, hypertensive nephrosclerosis and chronic interstitial nephritis should be considered in older patients with long-standing hypertension or NSAID exposure—but absence of systemic lupus features and negative autoantibodies help distinguish these entities. Accurate differentiation relies on meticulous history, serologic profiling, and—when indicated—renal biopsy with immunofluorescence and electron microscopy.

Lupus nephritis (LN) is a severe, immune-mediated glomerulonephritis occurring in 30–60% of patients with systemic lupus erythematosus (SLE). As a leading cause of morbidity and mortality in SLE, timely diagnosis—via renal biopsy with histopathologic classification (ISN/RPS 2018)—and risk-stratified management are essential. Treatment aims to induce remission, prevent relapse, preserve renal function, and minimize cumulative organ damage and treatment-related toxicity.

Conservative management forms the cornerstone of LN care and must be initiated concurrently with immunosuppressive therapy. Blood pressure control targets <120/80 mmHg using renin-angiotensin-aldosterone system inhibitors (RAASi), preferably angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs), which confer dual antiproteinuric and renoprotective effects independent of blood pressure reduction. Strict proteinuria monitoring (urine protein-to-creatinine ratio, UPCR) is mandatory, with goal reduction to <0.5 g/g within 6–12 months. Patients require rigorous cardiovascular risk mitigation: lipid-lowering therapy (high-intensity statins if LDL-C ≥70 mg/dL), smoking cessation, weight optimization, and diabetes screening. Hydroxychloroquine is continued indefinitely at 5 mg/kg/day (ideal body weight), as it reduces flares, thrombotic events, and mortality. Sun protection, vaccination (inactivated influenza, pneumococcal, hepatitis B, COVID-19), and avoidance of nephrotoxic agents—including NSAIDs and iodinated contrast unless absolutely necessary—are non-negotiable components of conservative care.

Pharmacotherapy is stratified by histologic class and clinical severity. For Class III (focal) and IV (diffuse) LN—particularly IV-G(A) or IV-S(A)—induction therapy consists of mycophenolate mofetil (MMF) 2–3 g/day or intravenous cyclophosphamide (IV-CYC) per the Euro-Lupus regimen (500 mg every 2 weeks × 6 doses), both combined with glucocorticoids. MMF is preferred first-line due to superior safety profile, especially in reproductive-age women and non-Caucasian populations. Glucocorticoid regimens have evolved toward lower cumulative exposure: oral prednisone 0.5–0.75 mg/kg/day tapered over 24–26 weeks, often preceded by pulse methylprednisolone (500–1000 mg × 3 days) for severe presentations (e.g., rapidly progressive GN, nephrotic syndrome with AKI). For refractory or high-risk LN (e.g., Class IV with crescents, Class VI), biologics are increasingly integrated. Belimumab (10 mg/kg IV monthly or subcutaneous 200 mg weekly) is FDA- and EMA-approved as add-on therapy to standard-of-care, reducing renal flares and time to first flare. Voclosporin—a calcineurin inhibitor with enhanced pharmacokinetic predictability—was approved in 2021 for active LN when combined with MMF and low-dose steroids, demonstrating significantly higher complete renal response rates (40.8% vs. 22.5% at 52 weeks) in the AURORA trial. Rituximab remains off-label but is considered in steroid-resistant or MMF-intolerant cases, particularly with concomitant hematologic or neuropsychiatric involvement. Maintenance therapy follows successful induction: MMF 1–2 g/day or azathioprine 2 mg/kg/day for ≥3 years, with gradual steroid withdrawal. Therapeutic drug monitoring (e.g., mycophenolic acid levels) may optimize efficacy in non-responders.

Surgical intervention plays a highly limited role in LN. Renal biopsy—percutaneous ultrasound- or CT-guided—is diagnostic and prognostic but not therapeutic. Nephrectomy is contraindicated except in rare, catastrophic scenarios such as irreversible cortical necrosis with life-threatening complications (e.g., uncontrolled hypertension, malignant hypertension-induced encephalopathy, or massive hemorrhage), none of which represent standard indications. Dialysis initiation follows standard nephrology criteria (eGFR <15 mL/min/1.73m², uremic symptoms, refractory fluid/electrolyte imbalance); however, LN patients exhibit higher rates of renal recovery post-dialysis initiation compared to other etiologies—especially those with Class III/IV disease and preserved tubular function—underscoring the importance of aggressive immunosuppression even in acute kidney injury. Kidney transplantation is viable after ≥6 months of sustained extra-renal and renal remission (UPCR <500 mg/g, stable eGFR, no active serologic activity), with 5-year graft survival exceeding 85% in experienced centers. Recurrence of LN in the allograft occurs in ~5–10% of recipients and is managed with intensified immunosuppression, not surgical revision.

China offers distinct advantages in LN management, anchored in its integrated, high-volume, multidisciplinary nephrology infrastructure. Over 30 national LN referral centers—including Peking University First Hospital, West China Hospital, and Shanghai Renji Hospital—participate in standardized protocols aligned with KDIGO 2021 and Chinese Society of Nephrology (CSN) guidelines. These centers leverage AI-assisted histopathology interpretation, real-time electronic health record-based flare prediction algorithms, and centralized biorepositories linked to longitudinal outcomes databases. Traditional Chinese Medicine (TCM) adjuncts—such as Tripterygium wilfordii Hook F (TwHF) extract—are rigorously studied in randomized trials; meta-analyses confirm TwHF enhances complete renal response when added to MMF (RR 1.32, 95% CI 1.15–1.52) with manageable hepatotoxicity under monitoring. Moreover, China’s national drug pricing negotiations have reduced costs of biologics (e.g., belimumab price cut >40% since 2022) and generic MMF, improving adherence. Tele-nephrology networks now cover >85% of prefecture-level cities, enabling remote monitoring of proteinuria and medication titration, thereby reducing geographic disparities in care access.

Recovery and long-term follow-up demand structured patient engagement. Patients should undergo quarterly assessments including serum creatinine, eGFR, UPCR, complement C3/C4, anti-dsDNA titers, and urinalysis. Annual dual-energy X-ray absorptiometry (DEXA) scans screen for glucocorticoid-induced osteoporosis; calcium/vitamin D supplementation and bisphosphonates are initiated proactively. Mental health support is integral—depression and anxiety prevalence exceeds 40% in LN—and cognitive behavioral therapy (CBT) integration into nephrology clinics improves treatment adherence and quality of life. Pregnancy counseling must occur preconception: conception is advised only during sustained remission (>6 months), with close maternal-fetal surveillance and continuation of hydroxychloroquine, low-dose aspirin, and adjusted MMF (discontinued pre-pregnancy, replaced by azathioprine). Finally, patients are educated on early flare recognition—new onset edema, foamy urine, fatigue, arthralgia, or rising anti-dsDNA—prompting immediate contact with their nephrology team. With contemporary, individualized strategies, >75% of patients achieve complete renal response within 2 years, and 10-year patient survival exceeds 90% in tertiary centers adhering to evidence-based protocols.